Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics confirmed that enrollment for Cohort 1 of its OPGx-BEST1 Phase 1/2 trial is complete, with five participants treated at a dose of 1.5E9 vg/eye. The company expects to announce three-month topline data in the second week of September 2026, contingent on participants completing scheduled assessments.
Key figures
- Drug Name
- OPGx-BEST1
- Phase Of Trial
- Phase 1/2
- Cohort1 dose
- 1.5E9 vg/eye
- Cohort2 dose
- 4.5E9 vg/eye
- Us prevalence
- 8400
- Global prevalence
- 21800
- Cohort1 participants
- 5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.